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Hepatitis B virus (HBV) replication involves virus-host cell interactions. The 
identification of host cell factors involved in HBV infection can enhance the 
understanding of viral replication, pathogenesis and potential. Transcriptome 
analysis by RNA sequencing was done with HBV-infected cells to identify gene 
expression changes due to viral infection. In this thesis, quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) was used to validate and 
analyses selected genes, and potential roles in viral replication. Additionally, 
cellular genes associated with the development of hepatocellular carcinoma 
(HCC) were identified as having altered gene expression. Analysis of HBx 
expression and selected HBx mutants on cellular gene expression revealed 
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Basic biology and replication of hepatitis B virus 
 Hepatitis B virus (HBV) is a hepatotropic DNA virus that causes an acute 
and chronic infection. Perinatal and early infants’ infection of HBV increases the 
risk of developing chronic hepatitis, which remains a major health burden 
worldwide (1, 2). Without effective therapeutic intervention, 25-40% of the chronic 
HBV carriers can develop liver fibrosis, cirrhosis, and even hepatocellular 
carcinoma (2). The World Health Organization estimates that in 2015, 257 million 
people were chronically infected with HBV, and 887,000 of them died from HBV-
related liver diseases, despite widespread HBV immunization (178). Currently 
approved therapeutics, including interferon- α (IFN- α) and nucleoside reverse 
transcriptase inhibitors (NRTIs), can effectively suppress viral replication. 
However, they cannot completely clear the infection. Furthermore, their 
therapeutic potentials are limited by subsequent adverse effects and emerging 
RT mutations that confer drug resistance due to prolonged use (3-5). Therefore, 
alternative therapeutic options are desperately needed to address this global 
health burden.  
 The infectious HBV virion is 42 nm in diameter and comprises an outer 
envelope of surface antigens (HBsAg), an inner nucleocapsid core, a virally 
encoded polymerase, and a partially double-stranded viral genome of 3.2 kb (6-
8). It is the smallest DNA virus with a genome that encodes four open reading 
frames (ORF) that are partially or wholly overlapping (8). Upon infection, the viral 
life cycle of HBV is heavily dependent on the interaction between the virion and 
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cellular host factors, from entry to secretion. Several cellular factors that interact 
with the virus are revealed to play critical roles in the HBV life cycle and become 
the targets for antiviral purposes (9). For example, Yan et al. identified sodium 
taurocholate co-transporting peptides (NTCP) (10), a bile acid transporter 
expressed in the liver as the receptor for HBV and HDV. It is encoded by the host 
SLC10A1 gene and typically regulates the uptake of bile salts into hepatocytes 
(11).  Upon HBV infection, the N-terminal myristoylated PreS1-region of L-protein 
of HBV binds to the NTCP receptor on the sinusoidal plasma membrane in high 
affinity to initiate the viral entry (10, 12, 13). The discovery of this virus-host 
interaction leads to the development of many host-targeting agents, including 
myrcludex B (an HBV preS1-derived synthetic lipopoly-peptide that binds to 
NTCP and block HBV infection), cyclosporin A (CsA) (an immunosuppressant 
that blocks the transporter activity of NTCP), and R041-5253 ( a selective 
antagonist of the retinoic acid receptor (RAR) with the ability to downregulate the 
expression levels of NTCP to reduce the host susceptibility to HBV infection) (12, 
14, 15). A major challenge that hinders the development of HBV antivirals is the 
unclear characterization of cellular factors and their functions in the viral life 
cycle, especially at the process of uncoating and synthesis of covalently closed 
circular DNA (cccDNA) that constitutes the template for all viral mRNA (9). 
Therefore, the search of host factors that interact with HBV can provide insight 
into a complete viral life cycle mediated by viral-host interactions and further help 
identify potential antiviral targets.  
3 
 
 RNA Sequencing (RNA-Seq) is a high-throughput sequencing-based 
approach that maps and quantifies transcriptomes to assess the overall functions 
and structure of genomes for interpreting the molecular mechanism underlying 
pathological conditions. A typical RNA-Seq experiment starts from converting the 
long RNAs to a library of cDNA attached to adaptors. The sequencing of each 
cDNA using high-throughput sequencing technology generates short sequence 
reads with sizes 30-400 bp. These resulting reads are aligned with the reference 
genome or transcriptome to produce a genome-scale transcriptional map that 
provides information regarding the structure and expression level of each gene 
(16). The functions and pathways of transcripts from RNA-Seq are analyzed 
through Gene Ontology (GO), Clusters of Orthologous Groups of proteins (COG), 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) database (17). The 
combination of RNA-Seq and other bioinformatics tools has been widely 
employed to identify potential cellular factors involved in viral infection and 
cancer development. In addition, it also reveals the role of host factors during 
pathogen infection to improve the understanding of viral-host interaction 
underlying pathogenesis (17-19). Yumeng McDaniel, a Ph.D. student in the lab of 
Dr. Louis Mansky, has previously conducted a transcriptome analysis of cellular 
gene expression changes induced by HBV infection. In that analysis, 220 genes 
were identified having altered expression, of which 131 were protein-coding 
genes. Among those 131 genes, (1) 14 genes were found to be previously 
reported to be related to HBV infection; (2) about 23 genes were found to be 
associated with other viral infections; (3) 13 of those 131 genes were noticed to 
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be associated with HCC development. The genes that had significantly altered 
expression upon HBV infection contain substantial potential for diagnosis and 
therapeutic intervention in HBV-related liver diseases. Therefore, it is necessary 
to investigate the underlying virus-host cell interactions and the mechanism of 
altered gene expression in HBV-infected cells. 
 The life cycle of HBV heavily relies on the interplay between the host and 
viral functions (9). HBV infection starts from the attachment of the antigenic loop 
(AGL) in the S domain of all surface antigens to the low-affinity HBV receptor, 
heparan sulfate proteoglycans (HSPG) on hepatocyte membrane (20, 21). 
Recently, Verrier et al. identified glypican 5 (GPC5) is another critical receptor for 
the initial attachment of HBV and HDV at the surface of hepatocytes (22). Upon 
the proteoglycan binding, HBV entry is processed by a more specific and higher 
affinity interaction of the myristoylated N-terminal polypeptide in the PreS1 
domain of the large surface antigen (L-HBsAg) and sodium taurocholate co-
transporting peptide (NTCP) on hepatocytes (10, 12, 13). The receptor binding is 
followed by the clathrin-mediated endocytosis regulated by the formed complex 
of L-HBsAg, clathrin, and its adaptor protein AP2 (23). Following viral 
internalization, HBV utilizes the Rab5 and Rab7-dependent transport through the 
endosome compartment to proceed viral uncoating (24). Nevertheless, 
information regarding the host factors and their functions during the de-
envelopment and nucleocapsid transport to the nucleus is limited (8, 9). It has 
been reported that the translocation of capsid to the nucleus requires the binding 
of nuclear localization signal (NLS) in the COOH-terminal of core proteins and 
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the nuclear pore complex (NPC) of the nucleus mediated by the nuclear transport 
factors importins (karyopherins) α and β (25). In addition, a protein of the nuclear 
basket, nucleoporin 153 (Nup153), is revealed to interact with the nucleocapsid 
for capsid disassembly and release of the viral genome - polymerase complex 
into the nucleoplasm after the binding of core and NPC (26).  
 The partial double-stranded genome, which is also called the relaxed 
circular (rc) DNA, comprises a complete minus strand (complimentary to the 
RNA) that covalently attached to the polymerase at its 5’ terminus and contains a 
terminal redundant sequence and an incomplete synthesized plus-strand with a 
covalently attached RNA oligonucleotide at its 5’ end (27). It is converted to the 
stable genomic template, covalently-closed circular (ccc) DNA for transcription of 
all progeny genomes. The conversion of rcDNA to cccDNA requires the removal 
of the polymerase, RNA primers on the 5’ terminus of the minus and plus-strand, 
and the filling and ligation of the gaps (28). Although the exact mechanism 
regarding cccDNA formation remains largely unknown, many studies speculate it 
mainly depends on the catalyzation of the cellular DNA repair machinery (27-29). 
Königer et al. reported that tyrosyl-DNA-phosphodiesterase (TDP) 2 can 
specifically cleave the tyrosyl-DNA phosphodiester bond that links the viral 
polymerase and rcDNA to release pol in the process of cccDNA formation (30). 
Another critical step of the conversion is the “filling the gap” or completion of the 
plus-strand synthesis of rcDNA. Previous studies examining the contribution of 
the viral polymerase in cccDNA formation of different hepadnaviruses uncovered 
that the selective inhibitor of the viral polymerase did not block the conversion, 
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implicating that cellular polymerase plays an important role (31-33). Recently, 
DNA polymerase κ encoded by POLK is reported to be essential for the cccDNA 
formation during de novo HBV infection in cell cultures. It is speculated that this 
cellular polymerase primarily contributes to the formation of cccDNA by filling in 
the gaps on the plus-strand of the rcDNA (34). Additionally, Flap endonuclease1 
(FEN1) is responsible for the removal of RNA or DNA primers during DNA 
synthesis at the lagging-strand and in DNA repair is involved in the cccDNA 
formation, presumably by cleaving the 5’-flap structure produced in the rcDNA-
specific structure (35, 36). DNA ligase 1 (LIG1) and 3 (LIG3) are required to seal 
breaks of rcDNA at the final ligation step of cccDNA formation (37). Double-
strand linear DNA (dslDNA) is a minor product of DNA replication that can 
convert to cccDNA via host cellular non-homologous end-joining pathways 
(NHEJ) and contribute to the integration into host chromosomes, which is a major 
mechanism of proto-oncogenesis of hepatocytes (38, 39). Ku80 and ligase 4 
(LIG4) are two components of the NHEJ pathway essential for converting 
dslDNA to cccDNA (37, 39).  
 The cccDNA is organized into nucleosomal complexes with histone and 
non-histone proteins in the nucleus of the infected hepatocytes (40). The 
minichromosome serves as the template for all five viral transcripts: (a) 3.5 kb 
precore mRNA, (b) 3.5 kb pre-genomic (pg), (c) 2.4 kb LHBsAg, (d) 2.1 kb MHBs 
and SHBsAg, and (e) 0.7 kb transcripts encodes X (8, 9).  
 The transcription activity of the supercoiled cccDNA is regulated by the 
recruitment of various proteins, including epigenetic factors, transcriptional 
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factors, chromatin-modifying enzymes, histone acetyltransferases, and 
deacetylase onto cccDNA. While the overexpression of histone 
acetyltransferases such as p300, CREB binding protein (CBP), p300/ (CREB 
binding protein) associated factor (PCAF) enhances HBV replication, the 
presence of deacetylases including histone deacetylase 1 (HDAC1) and hSirt1 
negatively regulate cccDNA transcription (41, 42). Moreover, protein arginine 
methyltransferase 5 (PRMT5) is identified to trigger a symmetric dimethylation of 
arginine 3 on H4 (H4R3me2s) on cccDNA to repress cccDNA transcription (43). 
The transcription of viral transcripts and HBV integrants is mediated by the host 
RNA pol II (44). The synthesized transcripts are then exported to the cytoplasm 
by the interaction between the core protein and the cellular factor Tip-associated 
protein/ nuclear export factor-1 (TAP/NXF1) for subsequent RNA translation, 
pgRNA encapsidation, and reverse transcription (45, 46). The five viral 
transcripts are translated to seven HBV proteins using the cellular translation 
machinery. The precore RNA encodes the precore protein, converted to the 
hepatitis B e-antigen (HBeAg) by the host furin endopeptidase (47). The 
bicistronic transcript, pgRNA, is responsible for producing the core (21 kD) and 
polymerase (90 kD) proteins. Moreover, it serves as the template for reverse 
transcription during HBV replication. Its transcript is even longer than the genome 
length, since it has a terminal redundancy of 120 nt that includes a second copy 
of the direct repeat (DR1) and the encapsidation signal ε, a stem-loop structure 
folded at 5’ end that facilitates the process of encapsidation, activation of 
polymerase, and reverse transcription (8, 48). The core subunits dimerize and 
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assemble for the formation of the nucleocapsid (49). The C-terminal of core 
proteins contains serine phosphorylation sites that regulate HBV viral replication 
and maturation (50).   
 The reported host cell kinases that mediate the phosphorylation process 
include cdc2-like kinases, cyclin-dependent kinase 2 (CDK2), Polo-like-kinase 1 
(PLK-1), Protein kinase C- α (PKC-α), SR protein-specific kinase 1 (SRPK1), and 
SRPK2 (51-55). Chen et al. reported that SRPK1 is a host kinase chaperone 
hijacked by HBV to regulate the core protein assembling and RNA-binding (56). 
PKC -α inhibition induces accumulation of intracellular capsid and reduced 
encapsidation capacity (57). The complex functions of other host kinases in the 
process of capsid assembly remain to be characterized. As the core subunits 
dimerize, the molecular chaperone heat shock protein 90 (Hsp90) binds to the 
core dimers. Hsp90 facilitates capsid formation, while another molecular 
chaperone, Hsp40, negatively regulates viral replication by enhancing the 
degradation of the viral core and HBx protein (58, 59). The polymerase binds to 
the encapsidation signal ε, and their interaction triggers the incorporation of the 
viral RNA and the pol into the capsid for nucleocapsid assembly (60). Host 
factors that assist their interaction include eukaryotic translation initiation factor 
4E (elF4E), Hsp90, and other cofactors (61, 62). The encapsidated pgRNA 
interacts with the tyrosine (Tyr) residues in the TP domain, RT domain, and 
RNase-H domain of pol to synthesize the minus-strand DNA, degradation of 
pgRNA, and the synthesis of the incomplete plus-strand DNA (63).The 
nucleocapsid containing the synthesized rcDNA can choose to be transported 
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back to the nucleus to replenish the cccDNA pool or be enveloped with the 
translated surface antigens and released as infectious particles.  
 HBV surface antigens are translated from the 2.4 kb L-HBsAg and 2.1 kb 
MHBs and S-HBsAg transcripts. The 2.4 kb mRNA transcript encodes the largest 
surface antigen, 42 kD L-HBsAg, which constitutes Pre-S1, Pre-S2, and S 
regions. In comparison, the 2.1 kb mRNA transcript expresses a middle-sized 33 
kD M-HBsAg that contains the Pre-S2 and S region, and the smallest 26 kD S-
HBsAg only with S region (8, 9). Once the surface polypeptides are translated, 
they are post-translationally modulated by N-glycosylation and transported to the 
membrane of the endoplasmic reticulum (ER) by the topogenic signals of the S 
region (64). M-HBsAg, however, contains an additional N-linked glycosylation 
site and an O-glycosylation site at its N-terminus (65). L-HBsAg is modified by N-
terminal myristoylation that is critical for viral infectivity (60). The maturation of 
the M and L-HBsAg requires the folding of the envelope proteins facilitated by the 
N-glycan processing, Hsp70, and ER-resident proteins BiP and calnexin. Rather, 
S-HBsAg utilizes the ER luminal protein disulfide isomerase (PDI) for its 
maturation during the envelope assembly. For viral particle assembly, the 
synthesized nucleocapsid is recognized and engaged by the NEDD4 E3 ubiquitin 
protein ligase (NEDD4). Ubiquitinated NEDD4 interacts with γ2-adaptin attached 
to the L-HBsAg due to the recognition by the ubiquitin-interacting motif of γ2-
adaptin. The HBV/NEDD4/ γ2-adaptin-pre-assembly complex is further 
processed to viral assembled particles in multivesicular bodies (MVBs) by 
recruiting ubiquitin-binding ESCRT-II complex, ESCRT- III, and Vps4 that 
10 
 
regulate intraluminal budding and membrane fission. MVBs and MVB-derived 
exosomes fuse with the plasma membrane and released assembled viral 
particles (66).  
 The smallest mRNA transcript (0.7 kb) encodes a 154-amino acid protein, 
X protein (67). It is a multifunctional protein localized in the cytoplasm, nucleus, 
and mitochondria of the infected hepatocytes (68). In the nucleus, HBx stimulates 
transcription by its interaction with different transcription factors, including cAMP 
response element-binding protein (CREB), RNA polymerase binding protein 
(RBP5), transcriptional factor IIB (TFIIB), transcriptional factor IIH (TFIIH), and 
nuclear factor kappa B (NF-κB). HBx also modulates the cytoplasmic signaling 
transduction pathways, including P13K/Akt, PKC, JNK/STAT, and 
Ras/Raf/MARK via calcium release (69-71). Furthermore, HBx interacts with 
other host factors relevant to apoptosis, DNA repair, cell proliferation, and 
epigenetic changes to promote the persistent HBV infection and even the 
development of hepatocellular carcinoma (HCC) (69, 72). Although the exact 
contribution of HBx in the replication cycle remains enigmatic, many studies have 
indicated that HBx enhances the replication efficiency of HBV, both in vitro and in 
vivo models. A lower level of the virus was observed in the hepatoblastoma 
HepG2 cell transfected with the plasmid containing HBx-defective HBV genome 
(41, 73), but it can be restored to the average level by co-transfection of the 
plasmid containing the wild-type HBV genome (74, 75). Similar observations 
were seen in independent animal models. The transgenic mice carrying the X-
defective HBV genome generate less virus than the mice with X-intact HBV 
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genome (76, 77), but crossbreeding of X-negative and positive transgenic mice 
can rescue the virus titers (77). Similarly, woodchucks receiving an intrahepatic 
injection of a plasmid carrying WHx-negative HBV genome showed less virus 
replication to those with wild-type HBV genome (78). These pieces of evidence 
mutually support that HBx boosts HBV replication.  
 To further investigate the specific role of HBx in the HBV replication, 
Belloni et al. targeted the HBV cccDNA transcription step by comparing the 
cccDNA copies and levels of pgRNA in HepG2 cells transfected with wild type or 
HBx mutant virus. Only the level of pgRNA was significantly reduced in cells 
carrying the HBx mutant HBV genome, implying that HBx participates in 
regulating the cccDNA transcription (41). HBV minichromosome transcription and 
HBV replication are largely associated with the acetylation status of HBV 
cccDNA-bounded H3 and H4 histones. During the transcription step, HBx protein 
regulates the recruitment of acetyltransferase and deacetylase onto cccDNA to 
influence HBV replication (41, 42). Recently, Kim and Siddiqui reported that HBx 
recruits methyltransferase onto cccDNA to induce N6-methyladenosine (m6A) 
modification of the viral RNA for increasing viral replication. In contrast, m6A 
modification mediated by HBx-methyltransferase interaction destabilizes the 
stability of host RNA, including phosphatase and tensin homolog (PTEN), with 
well-characterized tumor suppressor activity (79). The association between HBx 
and hepatocellular carcinoma has been intensively studied since Kim et al. 
reported that the transgenic mice with the expression of HBx in their liver 
developed liver tumor (80).  
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HBV-associated hepatocellular carcinoma 
 Hepatocellular carcinoma (HCC) is one of the main cancer-related causes 
of death worldwide. The general 5-year survival rate for liver cancer patients is 
3% to 34%, depending on the clinical stages of the tumor diagnosed (179). 
Chronic hepatitis B and C infection are the major risk factors of HCC and 
contribute to 80% of HCC cases globally (81, 82). Common mechanisms for 
HBV-promoted HCC are associated with HBV DNA integration into host genome 
(83, 84), HBV-encoded oncogenic protein X (69, 71), and accumulated damages 
in hepatic inflammation (83). Many studies revealed that HBx promotes the 
development of HCC via several strategies. COOH-terminal truncated (Ct) HBx is 
the most common integrant that is frequently detected in HCCs (85). Compared 
with full-length HBx, Ct-HBx can transform immortalized cell lines such as MIHA 
and HepG2 more efficiently. Sze et al. determined that the increased cell-
invasiveness of HepG2 is induced by the activation of C-Jun protein and matrix 
metallopeptidase 10 (MMP10) by Ct-HBx (85, 86). Furthermore, Ct-HBx 
transactivates the nuclear factor of activated T cells 2 (NFATC2) to suppress the 
activity of a critical regulator of glucose metabolism, thioredoxin interacting 
protein (TXNIP) in hepato-oncogenesis (87). Ct-HBx has a weak pro-
carcinogenic role due to the incapability of tumor development in Ct-HBx 
transgenic mice. Rather, Ct-HBx can enhance diethylnitrosamine (DEN)-induced 
hepatocellular carcinogenesis in transgenic mice (88). Another relevant pro-
carcinogenic activity of HBx in the activation of oncogenic signaling pathways by 
HBx and its isoforms. HBx can promote the malignant transformation of the 
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human hepatic cell line L02 via activation of the Notch signaling pathway. The 
activation of this signaling pathway affects the expression levels of an apoptotic 
suppressor Bcl-2, CDK inhibitor p16, and NF-κB (89). Ser31 phosphorylation of 
HBx by Akt contributes to hepato-oncogenesis via enhancing the transformation 
of NIH3T3 cells with activated ras oncogene (90). In addition, HBx can activate 
other oncogenic signaling pathways such as PI3K/Akt-mTOR (91) and Wnt/β-
catenin pathway (92) for mediating cell proliferation, regeneration, and apoptosis 
in HCC development. The interaction of HBx and host factors also provide useful 
information regarding the pro-oncogenic role of HBx. HBx upregulates the 
expression of a proto-oncogene src substrate, cortactin (CTTN), and their 
interaction affects CREB1 and its downstream targets, including Bcl2 and matrix 
metalloproteinase 9 (MMP9), to modulate cell proliferation, migration, and 
oncogenic signaling pathways (93). HBx can also cause upregulation of a cellular 
regulation factor, sirtuin 1 (SIRT1), to promote hepatocarcinogenesis (94). 
Although these data support a strong correlation between HBx activity and 
hepato-oncogenesis, a comprehensive mechanism of HBx-promoted HCC 
remains elusive. Searching for novel HCC-related host factors that interact with 
HBx may improve the current understanding of the etiology of HBx-related 
hepato-oncogenesis.  
Thesis goals and objectives 
 Yumeng McDaniel (Ph.D. student, laboratory of Louis Mansky) confirmed 
gene expression changes of 18 selected genes related to HBV or other viral 
infections using real-time quantitative PCR (qRT-PCR). Here, the role of viral 
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factors in regulating the expression of the 18 cellular genes was characterized for 
a better characterization of host-viral interaction in HBV infected cells. 
Expression of host genes in the presence of individual HBV protein was 
quantified by qRT-PCR and compared with mock/vehicle control. In this study, it 
was found that the individual HBx or polymerase expression did not induce the 
alteration of those cellular gene expressions observed in HBV-infected cells. 
HBV capsid downregulated SRFBP1, an essential factor involved in the post-
fusion entry process upon HCV infection (95). L-HBsAg and S-HBsAg triggered 
the downregulation of FBLIM1 (a cell junction protein), NMT1 (an enzyme with 
Protein-N myristoylation activity), and NPR2 (a receptor with guanylate cyclase 
activity). However, M-HBsAg was incapable of downregulating these genes. 
Additionally, using RNA interference assay, we observed the elevated HBV 
infection rate with the knocking down of SRFBP1, and reduced infection rate with 
the knocking down of FBLIM1. To explore the mechanism of HBx-promoted 
hepato-oncogenesis, the effect of HBx on the expression of the 13 HCC-related 
genes was also investigated. The data showed that individual HBx expression 
only induced the up-regulation of SSTR5 (a subtype of the somatostatin receptor 
family) and FLG2 (a protein required for proper cornification) but not the other 10 
genes. Moreover, the study of HBx domain(s) critical for viral oncogenesis 
demonstrated that HBx_F30V and HBx5 mutants differently regulated the 
expression of four cancer-related genes, HOMER2 (a member of homer family of 
dendritic proteins), NFYC (a heterotrimeric transcription factor subunit), TP53 (a 
tumor suppressor), SSTR5 and FLG2. Taken together, the data presented here 
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offer new insights about HBV-host interaction and HBV-related HCC 
development, thus contributing to defining novel anti-HBV targets for improving 
































Materials and Methods 
Cell lines and plasmids 
 The HepG2 and HepAD38 cell line was a kind gift from Dr. Daniel D. Loeb 
(University of Wisconsin-Madison, Madison, WI). The HepG2-NTCP cell line was 
graciously provided by Dr. Haitao Guo (Indiana University, Indianapolis, IN).  
 The plasmid pHAGE mNeonGreen-Core (HBc from HBV) IRES puro was 
a gift from Raphael Gaudin (Addgene plasmid # 122202) (96). HBx, pol, S-
HBsAg, M-HBsAg and L-HBsAg were gifts from Wang-Shick Ryu. (Addgene 
plasmid # 65463; 65520; 103013; 103012; 103011) (97-99). pGFP-HBx was a 
gift from Xin-Wang. (Addgene plasmid # 24931) (100). 
 The plasmids pCMV-deltaX and pHAGE-mNeonGreen-deltaCore were 
modified from HBx and pHAGE mNeonGreen-Core (HBc from HBV) IRES puro, 
respectively. Briefly, X gene or Core gene were deleted from template plasmids 
through three rounds of PCR. In the first PCR reaction, linear DNA templates 
were generated using primers HBx_F0 and HBx_R0, or primers HBc_F0 and 
HBc_R0 to exclude x or core genes. Using the linear DNA templates generated 
in the first PCR, fragment pCMV-deltaX1 was produced using primers 
HBx_Ampicillin_F1 and HBx_blank_R1 during the second PCR, while fragment 
pCMV-deltaX2 was formed using primers HBx_blank_F2 and HBx_Ampicilin_R2 
during the third PCR. Using the linear DNA templates generated in the first PCR, 
fragment pHAGE-mNeonGreen-deltaCore 1 was produced using primers 
HBx_Ampicilin_R2 and HBc_blank_R1 during the second PCR, while fragment 
pHAGE-mNeonGreen-deltaCore2 was formed using primers HBc_blank_F2 and 
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HBx_Ampicilin_F1 during the third PCR. For the last step, pCMV-deltaX1 and 2 
fragments were ligated using Gibson Assembly Master Mix (New England 
BioLabs Inc.). So were pHAGE-mNeonGreen-deltaCore 1 and 2 fragments. 
Ligation products were transformed into E. coli, and vectors were purified 
(Monarch ® Plasmid Miniprep Kit, New England BioLabs Inc) and sequenced 
using CMV-F or HBc blank-Sanger primer. Sequence alignments were performed 
using the SeqMan assembler of the Lasergene 7 software package (DNAStar, 
Madison, WI). The plasmid pcDNA3.1+C-HA was purchased from GenScript and 
the HA tag was deleted.  
 The HBx5 and HBx_F30V mutants were generated from HBx plasmid 
through site-directed mutagenesis using the Gibson assembly approach. DNA 
fragments 1 and 2 of both mutants were prepared with appropriate site-directed 
mutagenesis primers in two rounds of PCR. The ligation of fragments 1 and 2 of 
each mutant was carried out by Gibson Assembly Master Mix (New England 
BioLabs Inc.) according to the manufacturer’s protocol. The ligation products 
were transformed into E. coli, and mutants were purified (Monarch ® Plasmid 
Miniprep Kit, New England BioLabs Inc.) and sequenced using HBx_Sanger_F 
primer. Both mutant clones were verified through sequence alignments on the 
SeqMan assembler of the Lasergene 7 software package (DNAStar, Madison, 
WI). Primers used are listed in Table 1.  
Cell Culture 
 HepG2 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal clone 3 (FC3) serum (HyClone, Logan, UT), 100 
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U/ml penicillin, 100 ug/ml streptomycin, and 100 U/ml MEM-NEAA (Life 
Technologies). HepAD38 cells were maintained in RPMI-1640 with 10% FC3 
serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 U/ml MEM-NEAA 10 mM 
HEPES, 0.4 mg/ml G418 and 0.3 μg/ml tetracycline. HepG2-NTCP cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM)-F12 supplemented 
with 10% FC3, 100 U/ml penicillin, 100 μg/ml streptomycin and 8 μg/ml 
blasticidin (101). All cell lines were maintained at 37 °C in 5% CO2.  
Production of virus stocks 
 The HepAD38 cell line produces HBV particles under the control of a 
tetracycline operator/CMV promoter (102) Five days following removal of 
tetracycline, cell culture supernatants were collected every other day till Day 29, 
pool together, and then concentrated to 70-100X by using a Vivaspin 20 ml 
100,000 MWCO (Sartorius) centrifuged at 2000 x g at 16°C. The virus was then 
aliquoted and stored at -80°C until use.  
Virus infection 
 HepG2-NTCP cells were incubated with HBV stock in the presence of 4% 
PEG8000 and 2% dimethyl sulfoxide (DMSO), centrifuged at 1000g for two 
hours, and then put in a 37 C CO2 incubator immediately. After 24 h, cells were 
washed with PBS once and media was replaced with fresh media containing 2% 
DMSO. 
RNAseq 
 The infected HepG2-NTCP cells were harvested three days post-infection. 
RNA was extracted from HepG2-NTCP cells with the High Pure RNA Isolation Kit 
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(Roche) and used for RNAseq. All samples passed initial QC, and NGS 
sequencing libraries were prepared using the Illumina Truseq library prep kit. All 
libraries passed QC and were sequenced up to 40-50M reads. Once obtained, 
FASTQ files were trimmed to remove adapter sequences. FastQ files were then 
converted to a SAM format and aligned using HISAT (Hierarchical Indexing for 
Spliced Alignment of Transcripts). HTseq was then used to obtain copies per 
million (CPM) values. CPM is the number of reads for a given gene relative to the 
total number of reads/million in a sample. For example, if gene A had 100 counts 
and there were a total of 50M reads then the CPM would be 100/50=2. The CPM 
data was then used for the analysis as described below. To determine gene 
expression, the DESeq2 method was used. Here, the CPM for the control 
samples were normalized to the mean total CPM for all genes for all control 
samples. The CPM for the treated samples were normalized to the mean CPM 
for all genes for all treated samples. These data were then filtered to remove 
genes where there were no copies detected (CPM=0) in any of the 6 samples. A 
second filter was applied to remove bias by removing samples where <2 control 
or treated samples gave CPM=0. Control and test samples were then compared 
and analyzed to determine statistically significant changes in CPM. Principal 
component analysis was performed to determine clustering between sample 
groups. 
pGFP-HBx transfection and flow cytometry analysis  
 HepG2 and HepG2-NTCP cells were grown in 24-well plates with a cell 
density of 150K/well or 200K/well one day prior to transfection. Both cells were 
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transfected with pGFP-HBx using Lipofectamine 3000 (Life Technologies). Media 
was replaced one day after the transfection. Four days post-transfection, cells 
were detached by trypsin EDTA and transferred to a 96-well plate. Cell pellets 
were collected after the centrifugation at 500 g for 5 minutes. At last, cells were 
stained with the staining buffer 1X PBS with 2% FC3 and then analyzed on an 
LSR II flow cytometer (BD Sciences) after being re-suspended with 2% fetal 
bovine serum in 1X PBS. Data analysis was performed using FlowJo and 
GraphPad Prism.  
Gel electrophoresis 
 The purified plasmids expressing individual viral factors, including HBc, 
HBx, pol, S-HBsAg, M-HBsAg and L-HBsAg were diluted 5-fold with sterile water 
and added with a 5X loading buffer. The prepared samples and a 1kb molecular 
weight- size marker was loaded on a 2% agarose gel stained with Ethidium 
Bromide. The electrophoresis was carried out at the voltage 120 V for 1 hour. 
Fractionalized bands were visualized under the UV light. The size of individual 
HBV factors was referred to that of the molecular weight-size marker.  
Quantification of viral RNA by qRT-PCR 
 HepG2-NTCP cells were grown in 24-well plates one day prior to 
transfection. Then HepG2-NTCP cells were transfected with pHAGE 
mNeonGreen-Core, HBx, pol, S-HBsAg, M-HBsAg, L-HBsAg using 
Lipofectamine 3000 (Life Technologies). The transfected HepG2-NTCP cells 
were harvested three days post-transfection, and their RNA was isolated with the 
High Pure RNA Isolation Kit (Roche). Next, cDNA synthesis was performed using 
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the iScript Selected cDNA Synthesis Kit (Bio-Rad) according to the 
manufacturer’s instructions. The synthesized cDNA was diluted 5-fold and 
quantified by qPCR using iTaq Universal SYBR Green Supermix (Bio-Rad). All 
Real-Time quantitative PCR was carried out using a Bio-Rad CFX96. The 
thermal cycling conditions for qRT-PCR were 95°C for 3 minutes, followed by 39 
cycles of 5 s at 95°C, and 60°C for 1 minute. Data were normalized to 18s rRNA 
expression. The used primers are listed in Table 2.  
Quantification of host RNA by qRT-PCR  
 Transfection of HepG2-NTCP cells with pHAGE mNeonGreen-Core, 
pHAGE mNeonGreen-deltaCore, HBx, pCMV-deltaX, pol, S-HBsAg, M-HBsAg, 
L-HBsAg, pCMV-EGFP, pHAGE-EGFP, pcDNA3.1 (delta HA tag), HBx5, or 
HBx_F30V was performed using Lipofectamine 3000 (Life Technologies). The 
expression of the antiviral or HCC associated genes was quantified using iTaq 
Universal SYBR Green Supermix (Bio-Rad). Data was normalized to 
mock/vehicle control. The sequence and information of the host gene primer sets 
are listed in Table 3.  
Transfection of DsiRNA 
 The hs.Ri. APOM.13.1, hs.Ri. APOL1.13.1, hs.Ri. SRFBP1.13.1, hs.Ri. 
FBLIM. 13.1, hs.Ri.CLDN5.13.2, hs. Ri. MAGI2.13.1, hs.Ri. TJP2.13.1 and 
scrambled negative control DsiRNA were purchased from Integrated DNA 




 Transfection of HepG2-NTCP with DsiRNAs was performed using the 
Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer's protocol. 20 nM was the final concentration for 
DsiRNAs. Transfection efficiency with a TYE 563 Transfection Control DsiRNA 
(Integrated DNA technologies, Coralville, IA) was 70-100% in these cells. 
Confirmation of the knock down of CLDN5, MAGI2, APOM, APOL1, SRFBP1 or 
FLG was confirmed by qRT-PCR.  
Statistical Analysis  
 Statistical analyses were, in part, implemented with GraphPad Prism, 
version 5.0 (GraphPad Software, Inc., La Jolla, CA). Statistical significance 
between groups was analyzed by either a one-sample t-test or by a one-way 
ANOVA test, as indicated. P values that were < 0.05 were concluded to be 














RNA sequencing analysis of HBV-infected cells 
To identify potential cellular factors associated with HBV infection, my colleague 
(Yumeng McDaniel, Ph.D. student in the lab of Louis Mansky) had formerly 
conducted a transcriptome analysis of cellular gene expression changes induced 
by HBV infection. HepG2-NTCP cells were infected with concentrated HBV virus 
stock. Total RNA was extracted and subjected to RNA-sequencing analysis. 
Genes with significant expression alteration were identified by DESeq2 
determining significant changes in CPM values for control and treated samples. 
In the transcriptome analysis, we found that expression of 220 genes is 
significantly altered in HBV-infected cells (Appendix Figure 1A). To further 
confirm the alteration of 220 gene expression in the control and treated samples, 
a principal component analysis was performed. Indeed, we observed the 
significant differences between the cluster groups (Appendix Figure 1B). These 
results suggest that these 220 cellular genes are potentially involved in HBV 
infection.  
Characterization of 220 significantly expressed genes using Gene Ontology 
Enrichment Analysis 
 Yumeng McDaniel (Ph.D. student, laboratory of Louis Mansky) 
characterized the 220 genes with significant expression changes in HBV- 
infected cells, using Gene Ontology Enrichment Analysis (Appendix Figure 2). 
Through the gene type analysis of these 220 significantly expressed genes, it 
was observed that 131 genes are protein-coding genes that encode functional 
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proteins, while the rest of genes either represent unmapped or transcribed into 
RNA molecules responsible for a variety of functions (Appendix Figure 2A and 
Appendix Table 1). To learn about the structural and functional information of 
these 131 significantly expressed protein-coding genes, these genes were 
categorized based upon cellular components and biological processes that they 
are involved (Appendix Figure 2B and C). The products of most of the 
significantly expressed genes were found to constitute the extracellular region 
and plasma membrane parts of cells. In addition, it was observed that several 
biological processes are mediated by the products of these 131 protein-coding 
genes, especially activities related to response to stimulus, signaling and stress.  
Based on our observation from these analyses, these 131 protein-coding genes 
with significant expression changes encode products that construct cellular 
compartments or macromolecules of cells and regulate critical molecular 
activities to contribute to HBV infection.  
Confirmation of host genes involved in cellular antiviral response and HCC  
 Previously 131 genes were identified as significantly altered protein-
encoding genes in HBV infected cells, and some of these genes had been 
reported to be associated with virus infection and hepatocellular carcinoma 
development. Through searching literature relevant to the function and activities 
of these genes in viral and liver cancer formation, it was found that 42 genes 
were reported to be related to HBV or other virus infection, and 13 genes were 
involved in the development of hepatocellular carcinoma (Appendix Table 2). 
Then, the expression alteration of 18 cellular host genes in HBV-infected cells 
25 
 
was validated using qRT-PCR assay (Appendix Figure 3). These data indicate 
that HBV induces the significant expression changes of these 18 cellular genes 
and 13 HCC-related genes to support HBV infection and HCC development.  
Flow cytometric determination of transfection efficiency  
 Transfection is an important tool that introduces foreign nucleic acids into 
cultured animal cells for studying the functions of expressed genes and gene 
products in the cells (103). An effective method to determine transfection 
efficiency for assessing the expression level of transfected genes and gene 
products is using a flow cytometer to quantify the expression of the green 
fluorescence reporter protein (GFP) inserted into the plasmid transfected into 
cells (104). To determine the transfection efficiency of HepG2 or HepG2-NTCP 
cells, the plasmid HBx-GFP was transfected into cultured cells and GFP 
expression level was quantified (Figure 1). Results showed that the transfection 
efficiency of HepG2 cells is approximately 6.2% and that of HepG2-NTCP cells is 
nearly 8.2%. Similarly, data generated by Yumeng McDaniel resulted in a range 
of HepG2-NTCP transfection efficiency that was between 5% and 10% (data not 
shown), suggesting that the transfection rate of HepG2-NTCP cells, without 
optimization, potentially induces unstable gene expression.  
Confirmation of sizes and expression of individual HBV plasmids 
 The HBV genome encodes seven viral proteins, including three different-
size surface antigens, HBV polymerase, core protein, the e antigen and the HBx 
regulatory protein. Since e antigen is not essential for HBV infection and 
replication (105) and the size of plasmid expressing HBx has been previously 
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confirmed (data not shown), we chose plasmids expressing the other five viral 
proteins (Figure 2A).  Using 2% agarose gel electrophoresis, the sizes of these 
plasmids were confirmed (Figure 2B). Next, the expression of individual HBV 
plasmids was validated (Figure 2C). The large expression of HBx regulatory 
protein, core protein, and polymerase was observed in the plasmid transfected 
cells. In addition, it was found that three domains of HBV surface antigens are 
expressed in cells transfected with L-HBsAg. Cells transfected with M-HBsAg 
showed expression of PreS2 and S domains. Lastly, there was only expression 
of S-domain in S-HBsAg transfected cells. These results match with the reported 
expression of three envelope protein domains. Altogether, the sizes and 
expressions of individual HBV plasmids were confirmed.  
Examination of individual viral factors regulation on the expression of 
cellular genes  
 To determine whether the expression of viral factors causes the alteration 
of host gene expression, I tested the regulation of viral genes on the expression 
of 18 significantly expressed genes in HBV infected cells (Figure 3). The data 
showed that the expression of HBx and polymerase do not induce changes of 
these cellular gene expressions (Figure 3A and 3C). However, the HBV capsid 
significantly downregulates SRFBP1, a cellular factor required for HCV entry (95) 
(Figure 3B). L-HBsAg and S-HBsAg cause the downregulation of FBLIM1 (a cell 
adhesion protein with filamin-binding activity), NPR2 (the primary receptor for C-
type natriuretic peptide), and NMT1(N-myristoyltransferase), but M-HBsAg does 
not alter the expression of these genes (Figure 3D and 3E). In addition, Yumeng 
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further explored the functions of these significantly expressed genes in HBV-
infected cells, using RNA Interference assay (Appendix Figure 4). Intriguingly, 
the data showed the elevated HBV infectivity with the knocking down of SRFBP1, 
and reduced HBV infection rate with the knocking down of FBLIM1. Thus, based 
on these results, it was showed that HBV capsid protein induced the 
downregulation of SRFBP1, and the knocking down of SRFBP1 increased HBV 
infectivity. Furthermore, FBLIM1 was downregulated by L-HBsAg and S-HBsAg, 
and HBV infection rate decreased with the knock down of FBLIM1. These 
observations indicate that SRFBP1 is potentially an antiviral cellular factor 
interacting with HBV capsid upon HBV infection. In contrast, FBLIM1 could be a 
critical cellular factor supporting HBV infection, and its expression is majorly 
regulated by L-HBsAg and S-HBsAg in HBV infected cells.  
Exploration of the mechanism of HBx-promoting hepato-oncogenesis  
 Because HBx had been reported to be associated with the formation of 
hepatocellular carcinoma (89-94), it is necessary to investigate whether the 
expression of HBx causes the alteration of the 13 HCC-related gene expression 
(Figure 4A). Surprisingly, wild-type HBx was observed to induce the upregulation 
of a few HCC-related genes, including TP53 (a tumor suppressor), SSTR5 (a 
subtype of somatostatin receptor family) and FLG2 (a protein required for proper 
cornification), relative to the control expression. However, the upregulation of 
TP53 induced by the wild-type HBx was not different from the effect of the 
vehicle control, suggesting the upregulation of TP53 was mainly caused by the 
expression of vehicle control. Several sources have revealed that HBx mutants, 
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including C-terminal truncated HBx and point mutations heavily contribute toward 
the development of hepatocellular carcinoma (85, 86, 88, 106). Ma et al. reported 
that COOH-terminal truncate HBx (79.3%; n=111) is very frequently detected in 
HCC tissues. Similarly, others found that compared with the full-length HBx, Ct-
HBx amplifies the downregulation of microRNAs (a class of small single-stranded 
non-coding RNAs majorly responsible for RNA silencing and gene regulation), 
increases the invasiveness of the immortalized human liver cell line HepG2, and 
enhances hepatocellular carcinogenesis induced by a carcinogen to promote 
tumor development. Additionally, some clinical studies have identified point 
mutations that show a high association with HCC, including I127T, V131I, 
F132Y/I/R, V5M/L, and F30V. Combinational mutations such as K130M/V131I 
double mutation, alternatively recognized as PreS mutation A1762T/G1764A also 
largely affect the disease progression to hepatocellular carcinoma in HBV-
infected patients (107-110).  To further explore the mechanism of HBx-promoting 
HCC at the viral-host interaction level, Huixin Yang (Ph.D. student, laboratory of 
Louis Mansky) and I planned to examine the regulation of closely-HCC related 
mutations of HBx on the expression of selected HCC-associated genes (Figure 
4B and 4C). Our current findings showed that HBx_F30V induces the 
upregulation of HOMER2 (a member of the homer family of dendritic proteins), 
TP53, SSTR5 and FLG2, while HBx5 upregulates NFYC (a heterotrimeric 
transcription factor subunit), SSTR5 and FLG2, suggesting that these two HBx 
mutants potentially adopt distinct mechanisms to contribute to HCC 
development. A former analysis had dissected X proteins into 6 domains based 
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on the homology of HBx from different mammalian hepadnaviruses (180) (Figure 
4B). Three conserved domains of HBx, A (aa 1-20, 90% homology), C (aa 58-84, 
86% homology), and E (aa 120-140, 90% homology) are interspaced by those 
more divergent domains B (aa 21-57, 60% homology), D (aa 85-119, 40% 
homology), and F (aa 141-154, 60% homology). To study the effect of a highly 
conserved mutant to HCC development, random residues on the conserved 
domains were selected to be mutated (Figure 4B) and would be tested whether 
it causes significant alteration of the expression of these HCC-related genes 





 The discovery of HBV has been one of the most considerable milestones 
related to public health and medicine in human history. During the 1960s, 
Krugman and colleagues identified two types of infectious hepatitis (infectious 
hepatitis (IH) and serum hepatitis (SH)) and distinguished their clinical, 
epidemiological, and immunological features (111). Also, work by Bloomberg and 
colleagues described the discovery of the Australia antigen (Au), as they 
observed the reaction between this antigen produced from an Australian 
aborigine and an antiserum derived from a hemophilic with transfusion. This 
antigen was later recognized as serum hepatitis antigen (SH) or hepatitis B 
surface antigen (HBsAg) and determined to be associated with serum hepatitis, 
or it is now known as HBV (112-114). Using electron microscopy in the 1970s, 
Dane and colleagues displayed the infectious virion particles in a 42 nm diameter 
(115). Starting from the 1970s, information regarding the structures of HBV 
(especially the viral genome and virion-associated proteins), biological, and 
clinical implications were revealed for a basic understanding of this long-existing 
virus since 3rd millennium B.C (116-119). Additionally, a prospective study 
conducted by Beasley and coworkers in Taiwan established the strong 
association between the virus and the development of HCC (120).  Extensive 
epidemiological studies confirmed the etiological role of HBV in 
hepatocarcinogenesis, identifying it as one of the main oncoviruses (121, 122).  
A major breakthrough of HBV treatments was the introduction of the plasma-
derived vaccine with validated efficacy in the early 1980s (123). The 
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development of subsequent recombinant vaccines expressed in yeast had 
similarly contributed to the dramatic reduction of the prevalence of HBV and 
incidence of HCC worldwide, especially in HBV- endemic countries (124). For 
example, the childhood HBsAg seroprevalence in Taiwan, a highly HBV-endemic 
area, decreased from 9.8% in 1984 to 0.7%, due to the long-established 
universal childhood hepatitis B vaccination (125). Correspondingly, the average 
annual incidence of hepatocellular carcinoma in children 6-14 years also reduced 
from 0.7 in 1981-1986 (prior to vaccination program) to 0.36 per 100,000 children 
in 1990-1994 (post-vaccine era), demonstrating the substantial impact of HBV 
immunization (126).  
 Another historical landmark of HBV therapy was the development of 
effective anti-HBV treatment options in the 1990s, including IFN- α and NRTIs. 
IFN-α has a direct antiviral and immunomodulatory activity to suppress HBV 
replication noncytopathically in a finite period, while NRTIs only target the 
reverse transcriptase by acting as chain-terminators in viral DNA synthesis after 
incorporation into the elongating DNA chain (127, 128). One of the critical 
endpoints of anti-HBV therapy is HBeAg seroconversion, which represents the 
loss of HBeAg or the presence of anti-HBeAg in chronic HBV patients (129). 
Response to standard IFN-α treatment showed a moderate HBeAg 
seroconversion rate in HBeAg-positive patients. Usually IFN-α-induced response 
can be sustained after discontinuation of treatments, accompanied by an active 
immune response against the virus. However, a less durable sustained off-
treatment response was observed in HBeAg-negative patients that received IFN-
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α (130). Peginterferon (PEG-IFN), the interferon modified with a polyethylene-
glycol (PEG) group, is superior to IFN-α in inducing the loss of HBeAg and HBV 
DNA in HBeAg-positive and negative patients. Furthermore, PEG-IFN treatment 
maintains a higher sustained response rate relative to IFN-α therapy (129). 
Lamivudine, the first approved nucleotide analog, showed efficiency of HBeAg 
seroconversion and HBV DNA suppression, but its therapeutic potential is limited 
by the high rate of drug resistance mutations (131). Later approved nucleot(s)ide 
analogues, including entecavir, and tenofovir with low rates of drug resistance 
demonstrated more antiviral responses, especially suppressing HBV DNA by 6 
logs in 1-year treatment compared with lamivudine. Nevertheless, entecavir and 
tenofovir-induced response displays a low HBeAg seroconversion rate (~20% 
after 1 year and 40-50% after 5 years), indicating the life-long treatment required 
for chronic HBV patients (3).  
 Despite the widespread HBV immunization and antiviral treatment options, 
the HBV prevalence worldwide only demonstrated a minimal decrease from 4.2% 
in 1990 to 3.7% in 2005. Moreover, the population infected with chronic HBV 
even rose from 223 million in 1990 to 240 million in 2005, suggesting the need to 
develop more effective antiviral therapeutics (132). Currently, the major cellular 
factors and their functions involved in HBV life cycle have been uncovered, and 
such information promoted the identification and exploitation of some feasibly 
druggable targets (7). Nevertheless, more unknown host factors that interact with 
HBV and its proteins remain to be investigated. Here in this study, we explored 
the interaction between the single viral proteins and significantly expressed 
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cellular genes in HBV infected cells and identified some critical host factors with 
substantial antiviral potentials for enhancing the understanding of HBV-host 
interactions and enriching the landscape of HBV treatments.  
  The studies conducted in this thesis of cellular gene expression changes 
induced by viral factors demonstrated that individual viral proteins, especially 
HBx and polymerase, led to minimal changes in expression alteration of these 
significantly expressed genes in HBV-infected cells. This observation indicates 
that the significant expression changes in these 18 cellular genes were mostly 
induced by other aspects of HBV expression and/or replication. Yet, a few 
cellular factors were found that interact with HBV capsid and L-HBsAg, and they 
may be feasible anti-HBV targets. The first critical host factor is serum response 
factor binding protein 1 SRFBP1. SRFBP1 is responsible for the regulation of 
GLUT-4 (insulin-regulated glucose transporter) expression in adipose tissues 
(133), and cytoskeletal and muscle-specific genes (134, 135). Its overexpression 
induces changes of cellular morphology and reduction of actin content in cultured 
cells (135). It is localized in both the cytoplasm and nucleus. In the nucleus, it 
mainly regulates transcription, while it interacts with G actin in the cytoplasm. 
Additionally, SRFBP1 was reported as an HCV host entry receptor, recruited to 
the established HCV receptor CD81 to promote HCV infection. By testing the 
infectivity level of lentiviral pseudo particles carrying HCV glycoproteins in 
SRFBP1-silenced cells, Gerald and coworkers determined that SRFBP1 does 
not affect HCV receptor binding. Instead, it may support fusion uncoating. More 
evidence supported the role of SRFBP1 in viral coating: SRFBP1 was recruited 
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to CD81 upon HCV E2 glycoprotein or HCV exposure, and their co-localization 
was also detected in the Rab5-positive early or late endosome (136). 
Interestingly, in our study, it was found that the expression of SRFBP1 is 
downregulated by HBV capsid, a critical regulator of uncoating. Besides, our 
RNA interference assay implied that SRFBP1 may be a host factor that 
suppresses HBV infection, contrary to the supporter role in HCV infection. This 
information indicates that SRFBP1 is a possible host factor associated with the 
uncoating process in the HBV or HCV life cycle, but it shows different regulatory 
functions toward HBV or HCV infection.  
 The regulation of gene expression for these genes could be specific to 
hepadnavirus, since Gerold and colleagues reported that the SRFBP1 silencing 
does not affect the infectivity of other viruses such as vesicular stomatitis virus 
(VSV) or human coronavirus 229E (136). The mechanism of how the regulation 
of SRFBP1 supports HCV entry remains elusive. However, studies found that 
HCV modulates the actin-dependent hepatoma spread induced by the antibody 
engagement of CD81, suggesting a vital role of the cytoskeleton in HCV infection 
(137). In line with this, SRFBP1 mainly regulates cytoskeletal and muscle-
specific genes (135), and interacts with G-actin (136). It is possible that HCV 
takes advantage of SRFBP1 regulation of the cytoskeleton dynamic for 
supporting its entry. Similarly, HBV may alter the endogenous mechanism of 
cytoskeleton-dependent transportation regulated by SRFBP1 to promote its 
infection and this alteration could be achieved by the interaction between HBV 
capsid and SRFBP1. Future studies including immunoprecipitation and 
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colocalization of HBc and SRFBP1, relative expression of SRFBP1-related 
cytoskeletal genes with the expression of HBc or in HBV-infected cells, and the 
effect of HBc-SRFBP1 interaction to cellular morphology are necessary to further 
validate the proposed functions and mechanism of SRFBP1 in HBV life cycle.  
 Another important host factor identified is filamin binding LIM protein 1 
(FBLIM1), also known as migfilin. It is a component of cell-extracellular matrix 
(ECM) adhesions that contains three structurally distinct regions: A C-terminal 
region with LIM domains, a filamin-binding N-terminal region, and a central 
proline-rich region (138, 139). The C-terminal region of migfilin binds to Mig-2, a 
component of cell-ECM adhesions required for cell shape modulation and was 
co-localized with Mig-2 at cell-ECM adhesions to regulate cell spreading. The 
migfilin N-terminal region interacts with the C-terminal domain of filamin to 
mediate the association of migfilin and actin filaments (139). Filamin is a class of 
proteins that consist of two 280 kDa subunits, and each subunit contains an 
actin-binding domain at its N-terminus and 24 repeats β-pleated sheet units 
(140). The binding of migfilin and filament is critical for actin assembly, as Tu and 
coworkers observed less filamentous actin in the migfilin-deficient cells (139). 
Since the dysregulation of cell adhesion could lead to the dissociation of cells 
and indirectly promotes metastasis, the functions of migfilin in the development of 
various cancers have been investigated (141). Former studies revealed that 
FBLIM1 is a multifunctional cell adhesion protein that interacts with different 
binding partners to either promote or suppress cell migration and invasion (141-
144). For example, FBLIM1 promotes GSK-3β-mediated β-catenin degradation 
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to negatively regulate esophageal cancer cell invasion. (The accumulation of 
cytoplasmic β-catenin induces the nuclear translocation and initiation of the 
transcription of specific genes involved in oncogenic transformation (138).) On 
the other hand, FBLIM1 interacts with epidermal growth factor receptor (EGFR, a 
critical regulator of cellular processes including proliferation, survival, migration, 
and differentiation) to contribute to the increased cell migration and invasion in 
gliomas and oral squamous cell carcinoma cells (142, 143).  However, the role of 
FBLIM1 in viral infections remains to be characterized. In this study, we found 
that the knock down of FBLIM1 decreased HBV infectivity, suggesting a 
supportive role of FBLIM1 in HBV infection. Nevertheless, the data presented in 
this thesis has shown that FBLIM1 is downregulated in HBV-infected cells, and 
this downregulation could be caused by the expression of L-HBsAg and S-
HBsAg. A potential explanation to resolve the controversy between these results 
could be that FBLIM1 supports HBV infection via posttranslational regulation. 
Another speculation about the mechanism is that the downregulation of FBLIM1 
may further activate other binding factors to increase HBV infectivity.  
 Immunoprecipitation and co-localization of the L-HBsAg, S-HBsAg, 
FBLIM1 and FBLIM1-associated binding partners are necessary for enhancing 
the understanding of the modulation of FBLIM1 to the infection of a typical 
hepato-tropic virus. Moreover, we observed the downregulation of FBLIM1 
induced by L-HBsAg and S-HBsAg, suggesting the PreS1 and S domain of HBV 
surface antigens mediate the downregulation of this gene. To determine the 
residues responsible for the expression alteration of these genes, an examination 
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of L-HBsAg and S-HBsAg mutants’ regulation on the expression of FBLIM is 
necessary to be included in the future studies. The region of FBLIM1 that 
interacts with the PreS1 and S domain of HBV surface antigens could be also 
identified using deletion mutants. With more information regarding the interaction 
between the viral factors and these two important host factors being uncovered, 
SRFBP1 and FBLIM1 may become potential antiviral targets with improved 
therapeutic outcomes for HBV patients.  
 In this thesis, downregulation of NMT1 (N-myristoyltransferase 1) and 
natriuretic peptide receptor 2 (NPR2) were also observed and were due to the 
expression of L-HBsAg and S-HBsAg. Detection of the cytosolic and ribosomal 
fraction, NMT1 catalyzes myristoylation of substrate proteins, allowing them to 
carry membrane-targeting activities (145). In addition to cellular proteins, many 
viral proteins are N-myristoylated, including the envelope (E) protein of dengue 
virus (146), Gag or Nef of HIV-1 (147), L-HBsAg of HBV (148), VP4 of poliovirus 
(149), VP2 of the simian virus (150), and pp60src of Rous sarcoma virus (151). 
Myristoylation of viral proteins plays a critical role in regulating viral infectivity 
(148), replication, and RNA expression (152). The studies conducted as part of 
this thesis have revealed that NMT1 was upregulated in HBV-infected cells. This 
result coincides with the posttranslational N-myristoylation of L-HBsAg, which is 
critical for L-HBsAg to acquire infectivity (60). Similarly, Suwanmanee et al. 
observed the upregulation of NMT1 in dengue virus-infected dendritic cells at 1-, 
12-, and 36-hours post-infection and a decreased viral titer in NMT1-silenced 
dendritic cells, suggesting that the regulation of NMT1 at different infection 
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stages, from the membrane-associated viral entry to viral exocytosis facilitates 
DENV replication (146). Nevertheless, in the study of the NMT1 expression 
regulated by single HBV viral factors, it was found that the downregulation of 
NMT1 induced by L-HBsAg and S-HBsAg, contrary to the regulation of HBV.  
 There is no obvious explanation for the differences between the regulation 
of the intact HBV and single surface antigens to NMT1 expression, unless more 
information related to the viral- host interaction and co-localization is uncovered. 
However, based on the results from current studies, it can be concluded that 
NMT1 is an essential host factor in the life cycle of HBV and a potential antiviral 
target for HBV infection. NPR2, a transmembrane receptor with guanylyl cyclase 
activity upon binding with the ligand C-type natriuretic peptide (CNP) is 
expressed in chondrocytes and vascular smooth muscle cells (145). NPR2 is one 
of the human protein kinases (HPKs) that affect multiple host pathways to 
negatively regulate the replication of Influenza (153), but the mechanism remains 
inconclusive. Previously our observation showed the upregulation of NPR2 
caused by HBV infection, implying that some host pathways modulated by NPR2 
are involved in HBV infection. Interestingly, later we found that NPR2 expression 
was downregulated by L-HBsAg and S-HBsAg. This discovery, again, 
demonstrates the distinct interaction of this host factor with the complete 
infectious virion or the single viral factors, leaving the roles of NPR2 and its 
associated cellular pathways in the HBV life cycle to be further explored.  
 One unresolved issue that remains to be addressed from this study is the 
incapability of M-HBsAg in causing the downregulation of these three host 
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factors. In the early studies of the functions of HBV surface antigens, M-HBsAg 
was reported that its expression does not affect viral morphogenesis and 
infectivity (154, 155), leaving the function of preS2 domain inconclusive. Further 
investigation on the role of the preS2 domain of L-HBsAg was carried out and 
excluded the possibility of L-HBsAg preS2 region from modulating HBV infection 
(156). Such evidence may suggest that preS2 domain is dispensable for viral 
secretion and infection of HBV, while a complete life cycle of HBV requires the 
interaction with these cellular factors.  
 Despite extensive studies, the precise role of HBx protein in hepato-
oncogenesis is yet to be determined. Due to its pleiotropic functions, HBx may 
contribute to the development of HCC in several ways, including interfering the 
DNA repair pathway, regulating apoptosis, epigenetic modification and 
telomerase activity, and interacting with nuclear transcriptional factors or cellular 
signaling pathways (71, 157).  However, the causal role for HBx in liver 
carcinoma is not fully supported by current studies because of a few major 
limitations. The most critical issue in many in vitro HBx experiments is the lack of 
an authentic model for examining the effect of HBx with low-expression in HBV-
associated HCC (157). Furthermore, the pathogenesis of HCC requires long-
term liver inflammation caused by the destruction and renewal of liver cells, 
excluding the strong and direct connection between HBx and HCC (69). Instead, 
several other groups found the enhanced expression of c-Myc transgene, 
elevated hepatocytes proliferation, and increased focal lesions associated with 
the development of HCC, in HBx-transgenic mice that either crossed with c-Myc 
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oncomice or received treatment of carcinogen, suggesting that HBx could be a 
weak, assisting supporter in liver oncogenesis (158, 159).  
 Since the HBx protein is a trans-activator that constantly modulates the 
transcriptional activity of different transcriptional factors and promoters, its 
interactions with possible HCC-related host factors are intensively investigated 
for further deciphering the exact contribution of HBx toward hepato-oncogenesis 
(69). Based on the findings from former viral-host interaction studies, a few 
cellular factors such as cortactin (CTTN), and centrosomal P4.1-associated 
protein (CPAP) were identified to be upregulated by X protein for mediating cell 
migration and proliferation of HCC or enhancing the activities of HCC-associated 
signaling transduction cascade (93, 160).  However, more unknown HCC-
relevant host factors that interact with HBx are yet to be reported. In conjunction 
with this thesis, it was previously determined that 13 significantly expressed 
genes are associated with the development of HCC, using the data analysis and 
literature research of the 220 genes with significant expression changes 
identified from the RNA-sequencing analysis. Furthermore, the examination of 
expression changes of these HCC-related genes induced by X protein showed 
that the full-length HBx could only cause the upregulation of a few HCC-
associated genes, including SSTR5, and FLG2.  
 SSTR5 belongs to the family of somatostatin receptors that are commonly 
expressed in non-healthy and tumor tissues such as cirrhotic and HCC (161-
163). The binding of somatostatin analogues (SSAs) to SSTR, especially SSTR2 
and SSTR5 triggers the suppression of cell proliferation to inhibit tumor 
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development (161). Interestingly, the expression of SSTR5 was reported to be 
significantly decreased in HCC tissues, compared with the paired surrounding 
cirrhotic liver cells (161, 162).  
 While SSTR5 has been identified as an important HCC-associated factor, 
its interaction with the oncogenic protein HBx is yet to be revealed. This thesis 
has shown the significant upregulation of SSTR5 was triggered by the expression 
of HBx, implying that HBx could contribute to HCC development via interacting 
with HCC-associated factors such as SSTR5. In contrast, in HBV-infected cells, 
we observed the opposite expression changes of SSTR5, suggesting that this 
gene could induce antiviral response.  This discrepancy between the regulation 
of the single viral oncoprotein and intact infectious virion on SSTR5 remains to 
be elucidated, but it has further validated the association of HBV, including HBx 
with the hepato-oncogenesis. Lastly, the upregulation of FLG2 was also 
observed and was caused by the expression of HBx. Being a protein involved in 
the formation of the skin barrier (164), FLG2 was identified and its mutation 
percentage is related to the size of liver tumor (165).  Although the information 
regarding the functions of FLG2 in HCC development is limited, our observation 
of the interaction between FLG2 and HBx suggested that dysregulation of FLG2 
induced by HBx could promote HCC.  
 Compared with full-length HBx, C-terminal truncated and point mutants of 
HBx are more commonly detected from the tissues of HCC patients. The 
functions of some major HBx mutants in the formation or development of HCC 
have been reported (71, 110). In this study we examined the expression changes 
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of selected HCC-associated genes triggered by these major HBx mutants for 
enhancing our understanding of the mechanism of HBx-promoted hepato-
oncogenesis. These results have demonstrated that both the HBx mutants, 
HBx_F30V and HBx5, could induce the upregulation of more HCC-related genes 
than the wild-type HBx. In addition, the distinct regulation of these two HBx 
mutants was observed to different HCC-associated genes. Besides upregulating 
SSTR5 and FLG2, HBx_F30V also causes the expression changes of TP53 and 
HOMER2.  
 TP53 is classified as a tumor suppressor gene responsible for repairing 
DNA damage and apoptosis to prevent tumor formation (166). Mutations in TP53 
are common genetic abnormalities in human cancers, including HCC (167). HBx, 
the multifunctional regulatory protein, was revealed to suppress a wide range of 
TP53-related activities, such as p53 sequence-specific DNA binding, p53 
transactivation ability, and the interaction of p53 with other cellular factors related 
to nucleotide excision repair (168).  Despite being repressive to p53-associated 
functions, HBx was reported to controversially regulate the expression of TP53. 
The expression of p53 gene was significantly repressed by X protein in the 
hepatoblastoma cell line Huh7 and HepG2-K8 transfected with the full length 
HBx (169, 170). On the other hand, HBx mediated the upregulation of p53 to 
elevate the expression of proteasomal activator gamma (PA28γ) for inhibiting the 




 In this thesis, however, HBx wildtype did not induce expression change of 
TP53. Instead, the upregulation of TP53 was observed to be caused by the 
expression of HBx_F30V. Moreover, the upregulated expression of TP53 by 
HBx_F30V is contrary to the reported suppression effect of HBx to the p53 gene. 
This unusual finding might further suggest that mutation on the residue 30 of HBx 
is critical for the altered expression of TP53. Additionally, this HBx point mutant 
could adopt distinct pathways to modulate the functions of HCC-associated host 
factors such as TP53 for the purpose of promoting viral infection and liver tumor 
development. 
 HOMER2 is a scaffold protein that regulates intracellular calcium 
homeostasis. Recently it has been identified as a novel biomarker of HCC and its 
downregulation is closely associated with the development of HCC (165). 
Furthermore, the dysregulation of HOMER2 expression was reported to be 
involved in the tumorigenesis of endometrioid adenocarcinoma (EAC) and rectal 
carcinoma (RC) (172, 173), also demonstrating that the regulation of HOMER2 
on calcium homeostasis has significant impact in tumor development. Here we 
found the upregulation of HOMER2 induced by the expression of HBx_F30V, 
displaying an opposite regulation to the finding from the recent study (165). One 
potential explanation is that the upregulation of HOMER2 in HBV-infected cells 
helps HBV escape from immune responses, as Luo et al. mentioned that 
HOMER2 is able to inhibit the activation of T cells (172). On the other hand, the 
other HBx mutant, HBx5 could upregulate NFYC, SSTR5 and FLG2. NFYC is a 
subunit of a heteromeric transcriptional factor necessary for binding to the 
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CCAAT motif in the promoter region of many genes (174). It was reported to 
assist POU Class 5 Homebox 1 (POU5F1), a transcriptional factor that is 
associated with various tumors to regulate activities related to tumor 
development via interacting with other factors, including KAT2A, CCND2 and 
GPD2 (175). This thesis has shown that NFYC was upregulated by HBx5. 
Similarly, He et al. observed the upregulation of NFYC in liver hepatocellular 
carcinoma (LIHC) tissues (175). Taken together, such information might suggest 
that the NFYC is a critical supporter for tumor development, and its interaction 
with HBx5 could promote HCC.  
 The reason that accounts for the divergence between the regulation of the 
wildtype HBx and mutants on the expression of HCC-related genes requires 
further investigation. However, there was evidence indicating that the full-length 
HBx is mainly localized in the cytoplasm (169), instead of the nucleus for 
transactivation. Rather, some HBx mutants such as double truncation mutants 
HBx (61-124) were found in the nucleus. The nuclear localization of HBx (61-
124) was speculated to be induced by the exposed nuclear localization signal 
from the conformational changes of that mutant (169). It is possible that the 
indicated HBx mutants might trigger conformational changes to be localized in 
the nucleus to interact with more HCC-associated factors to contribute to HCC 
formation. Nevertheless, this speculation might not be tested until the crystal 
structure of HBx is revealed (176).  
 Despite the discovery of some host factors with significant antiviral values, 
this study still needs a few improvements to be more credential. The first 
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limitation of this study is the low transfection efficiency of HepG2-NTCP cells, 
which might lead to the unstable gene expression. According to the report from 
Nishitsuji et al., the general transfection efficiency of HepG2 cells should be 
greater than 35% (177). Since the transfection efficiency of HepG2 cells was only 
4% in this study, further specific optimizations are required to achieve high 
transfection efficiencies. Another restriction of this study is the single 
experimental design. Here, we mainly examined the regulation of HBV viral 
proteins on HBV and HCC-related host genes via qRT-PCR, due to the time 
limitations. Without time constraint, the addition of more experiments including 
immunoblot analysis, immunoprecipitation and co-localization would enhance the 
credibility and provide more useful information related to the host functions in 
HBV infection and HCC development.  
 In summary, the analysis of the regulation of single HBV viral factors to 
HBV-associated cellular genes was determined and identified host factors with 
potential therapeutic potential. Additionally, because the exact contribution of 
HBx to the formation of HCC remains elusive, the expression changes of HCC-
related genes induced by the wildtype and mutants of HBx was investigated. The 
results in this thesis have shown that the full-length HBx is a weak oncoprotein 
that rarely promote the development of HCC via interacting with host factors 
commonly expressed in HCC tissues, while HBx mutants can induce the 
dysregulation of more HCC-associated factors to be involved in the formation 
and development of HCC. The findings reported in this thesis reveals new 
information about viral-host interactions that may be important regarding HBV 
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infection and HCC development, thus enhancing our understanding of a 













































Table 1. Primers used to construct blank control and mutant plasmids 



















Table 2: Primers used to verify the expression of individual HBV factors 
Name Forward Primer (5’ to 3’)  Reverse Primer (5’ to 3’)  Expected 
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Figure 1. Flow cytometric determination of transfection efficiency of HepG2 
and HepG2-NTCP cells. A. Flow cytometry analysis. B. Quantitative 
analysis. HepG2 and HepG2-NTCP cells were transfected with pGFP-HBx. Four 
days post the transfection, cells were collected and stained with the staining 
buffer 1X PBS with 2% FC3 for flow cytometry. The amount of GFP fluorescence 
expression in each transfected cell was determined using an LSR II flow 
cytometer. Data analysis was performed using Flowjo and GraphPad Prism. 












































Figure 2. Confirmation of size and expression of individual HBV plasmids. 
A. Domain structures of HBV viral factors. The infectious HBV virion encodes 
seven viral proteins, including HBV surface proteins, viral polymerase, capsid-
forming core proteins, e-antigen and the multifunctional HBV X regulatory 
protein. Since e-antigen is not essential for HBV infection and replication, it is not 
shown in this figure. B. Agarose gel electrophoresis of extracted plasmids 
that express individual HBV factors. The size of DNA fragments representing 
individual HBV factors was referred to that of the molecular-weight size marker. 
Lanes 1 to 5 represent the following individual viral factors: HBV capsid, M-
HBsAg, HBV polymerase, L-HBsAg, and S-HBsAg, while lane M is the 1kb DNA 
size marker. C-D. Relative expression of individual viral factors was 
confirmed via qRT-PCR. HepG2-NTCP cells were transfected with plasmids 
expressing HBx, HBV core, HBV pol or L, M, S-HBsAg. After 3 days post-
transfection, cells were collected for RNA extraction and qRT-PCR. Data were 
normalized to 18sRNA expression. Results are shown as average ± standard 
deviation with two independent experiments.  
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Figure 3. The expression of most cellular factors is not altered by individual 
HBV factors in HBV infection. A-D.  HBx or pol do not induce expression 
changes in the cellular genes, while HBV capsid and L-HBsAg 
downregulate SRFBP1, FBLIM1, NPR2 and NMT1. HepG2-NTCP cells were 
transfected with plasmids that express HBx, HBc, pol or L-HBsAg. After 3 days, 
cells were collected for RNA isolation and qRT-PCR analysis. Data were 
normalized to mock and converted to log2 fold changes. E. L-HBsAg and S-
HBsAg cause the downregulation of FBLIM1, NPR2 and NMT1, while M-
HBsAg is incapable of downregulating these genes. The expression of three 
host genes affected by different surface antigens was quantified by qRT-PCR. In 
all panels, data were normalized to mock or vehicle control and converted to log2 
fold changes. Results are shown as medium  interquartile (IQR) with three 
independent experiments. The significant differences between the transfected 
samples and the mock control were analyzed by one – sample t-test and shown 
with asterisks “*”, above the relative box (A-D). The significant differences 
between the delta S and samples expressing L, M, S-HBsAg were analyzed by 
One-Way ANOVA and shown with asterisks “*” above the relative box (E). “ns” = 
not significant, which is not shown in the figures. “***” = p≤0.001; “**” = p≤0.01; 


























































































Figure 4.  HBx mutants are associated with the alteration of HCC-related 
gene expression. A. HBx wild-type alters few HCC-related gene 
expressions. HepG2-NTCP cells were transfected with HBx and at 3 days post-
transfection, cells were collected for RNA isolation and qRT-PCR. B. schematic 
presentation of HBx wild-type and mutants. HBx protein is dissected into six 
functional domains based on the homology between different mammalian 
hepadnaviruses. Shown at domain A, C, E are domains with more conserved 
residues. Also shown at domain B, D, F are domains with more variable 
residues. Below the domain structure of HBx is the list of HBx mutants used to 
test their effects on selected HCC-related gene expression. C. HBx_F30V 
mutant upregulates HOMMER2, TP53, FLG2 and SSTR5, while HBx5 mutant 
upregulates NFYC, FLG2 and SSTR5. The expression of selected HCC-related 
genes affected by HBx WT, F30V or HBx5 was analyzed using qRT-PCR. In all 
panels, data were normalized to mock control and converted to log2 fold 
changes. Results are shown as medium  IQR with three independent 
experiments. The significant differences between the samples expressing wild 
type HBx and the mock (A) were analyzed by one – sample t-test and shown with 
asterisks “*”, above the relative box. The significant differences between the delta 
X and samples transfected with HBx WT and mutants (C) were analyzed by One-
Way ANOVA and shown with asterisks “*” above the relative box. “ns” = not 
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Appendix Figure 1: Expression of 220 genes are significantly altered in 
HBV-infected cells. A. Heat map for the 220 significantly expressed genes. 
A heat map was generated to show the changes in expression. Genes are shown 
on the right column and samples are indicated. The tree at the top of the figure 
indicates the split between control and treated samples. The tree on the left 
indicates the gene family groupings for the 220 genes included. C 1/2/3 
represent control samples; T 1/2/3 represent treated/infected samples. B. 
Principal component analysis (PCA) of 220 significantly altered genes in 
control and treated samples. PCA shows the control (Blue) and treated (Red) 
samples are from two distinct clusters, indicating that there are significant 
differences between the groups. This analysis used the 220 gene dataset but 










Figure 3A. Gene type analysis of 220 significantly expressed genes using 
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Figure 3B. Cellular components analysis of 131 significantly 
expressed protein-coding genes using ShinyGO v0.61: Gene 






Appendix Figure 2: Gene Ontology Enrichment Analysis of genes having 
altered expression in HBV infected cells using ShinyGO v0.61. A. Gene type 
analysis of 220 significantly expressed genes. Shown is the categorization of 
genes based upon gene type. B. Cellular components analysis of 131 
significantly expressed protein-encoding genes. Shown is the categorization 
of protein-encoding genes. C. Biological process analysis of 131 significantly 
expressed protein-coding genes. Shown is the categorization of genes based 
upon their association with a biological process. 
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Figure 3C. Biological process analysis of 131 
significantly expressed protein-coding genes using 






Appendix Figure 3: Alteration of host gene expression was confirmed by 
qRT-PCR analysis. Cells were collected at 3 days post infection for RNA 
extraction and qRT-PCR. Results are shown as the average ± standard deviation 








Figure 4. Alteration of host gene expression was confirmed by qRT-PCR analysis. Cells were 
collected at 3 d.p.i for RNA extraction and qRT-PCR. Results are shown as the average ± standard 








































































































Appendix Figure 4: HBV infection is elevated with the knocking down of 
APOL1 and SRFBP1 genes, while decreased with the knocking down of 
TJP2 and FBLIM1 genes. Twenty-four hours post DsiRNA transfection, HepG2-
NTCP cells were infected with HBV having an infection rate from 12 to 25%. 
Cells were collected at 5 days post infection for HBc and Alexa Fluor 594 
secondary antibody staining, and flow cytometry analysis. Results are shown as 
the scattered dot plot with mean of six independent experiments. The significant 
difference between DsiRNA transfected samples and mock control was analyzed 
by a one sample t test, which is indicated by an “*” above the relative dot plot. 
The significant difference between other DsiRNA and negative scrambled 
DsiRNA treatment was analyzed by one-way ANOVA test, which shown with “✢” 



























Gene Type Gene Symbol
protein_coding 
C1orf159, TARDBP, FHAD1, FBLIM1, NFYC, DMAP1, SLC35D1, CLCA4, DBT, CLCC1, HRNR, FLG, FLG2, EIF2D, 
B3GALNT2, ADCY3, HAAO, CALM2, PEX13, GPR45, TFPI, CTDSP1, ABCB6, FANCD2OS, GHRL, SUSD5, GOLGA4, 
CCDC12, HEMK1, LSAMP, CCNL1, LCORL, GNPDA2, EXOSC9, SLC9A3, EGFLAM, MOCS2, CCNH, SRFBP1, 
NOP16, FAM153A, APOM, GPANK1, LGSN, NT5E, KIAA0895, STX1A, GNB2, ALKBH4, CYREN, MCPH1, FDFT1, 
MED30, HSF1, ACO1, NPR2, FRMD3, ANGPTL2, DBH, DIPK1B, SLC34A3, NODAL, MICU1, SHLD2, FAS, LMNTD2, 
C11orf21, BAD, RCE1, MRPL48, CCDC65, SLC11A2, SCN8A, ZNF385A, SLC26A10, PTPRB, VEZT, CIT, HNF1A, 
DDX55, ANKLE2, CAB39L, DNAL1, SIVA1, FSIP1, DNAJC17, RFX7, SLC24A1, HOMER2, POLG, NME4, RHOT2, 
SSTR5, DNASE1, PDXDC1, ATP2A1, MAZ, PRRT2, ABCC11, KATNB1, ZNF276, TP53, IFT20, RFFL, DHX8, NMT1, 
AFMID, SGSH, ENOSF1, INO80C, NDUFS7, BTBD2, PLEKHJ1, SMARCA4, CEBPG, YIF1B, C19orf54, PRR19, IGFL2, 
FTL, ZNF776, MGME1, ID1, MMP9, SYNJ1, SEC14L2, APOL1, CDSN, PRICKLE3, PLXNB3, DKC1, PEG13
antisense
TGFB2-AS1, LINC02576, SCN1A-AS1, ITIH4-AS1, PLCXD2-AS1, WDFY3-AS2, STARD4-AS1, TONSL-AS1, APOA1-
AS, TMPO-AS1, FUT8-AS1, TPM1-AS, PRC1-AS1, TMEM147-AS1, PLA2G4C-AS1, CARD8-AS1, FTCD-AS1
lincRNA LINC02067, ARRDC3-AS1, HIF1A-AS2
miRNA MIR4520-1







Appendix Table 2: Summary of gene functions based on current literature.a 
 
      
Category No. Genes Alternation Key Words Reference 
HBV associated 
1 APOM down HBV induced regulation PMID: 21875437, PMID: 31393946 
2 CTDSP1 down HBV restriction PMID: 25342750, PMID: 32265934 
3 ATP2A1 down HBV, paramyxovirus, virus-supportive PMID: 10871838, PMID: 30814986, 
4 FTL down Cellular attachment and entry of hepatitis B virus PMID: 22359459 
5 MMP9 up Facilitate HBV replication, upregulation by HBV; extracellular matrix organization PMID: 28122987, PMID: 12464265 
6 CCDC12 up HBV integration PMID: 31417659 
7 CEBPG up HBx, proliferation and migration of hepatoma cells PMID: 31621133 
8 EGFLAM up potential role in HBV induced non-hodgkin lymphoma; extracellular matrix protein PMID: 32350851 
9 FAS down HBV enhances the sensitivity of hepatocytes to fas-mediated apoptosis PMID: 30171166 
10 GHRL up HBV-related liver cirrhosis PMID: 26599409 
11 ID1 down degradation of HBx, HCC PMID: 31146743, PMID: 18674781, PMID: 20574154 
12 TARDBP down HBV replication PMID: 31186504 
13 HNF1A down Hepatocyte nuclear factor 1α downregulates HBV gene expression and replication by activating the NF-κB 
signaling pathway PMID: 28319127 
14 DNASE1 down cellular restriction factor of hepatitis B virus PMID: 30936483 
Other Viruses 
Associated 
15 ABCB6 down HCV-related HCC PMID: 23483087 
16 AFMID down Influenza virus related downregulation, HCC PMID: 31461941, PMID: 29449409 
17 APOL1 up HIV-1 related, anti-viral restriction factor PMID: 27599995 
18 SRFBP1 down HCV entry PMID: 26212323 
19 DMAP1 down Antiviral defense, immune evasion and oncogenesis PMID: 29438328 
20 NMT1 up Elevated in DENV replication, involved in picornavirus life cycle, HIV-1 production PMID: 30848105, PMID: 30080883, PMID: 18248763, PMID: 18089753 
21 NPR2 up Essential for influenza virus PMID: 23805279 
22 SIVA1 down Required for replication of influenza A virus PMID: 21048035 
23 DHX8 down HIV-1 replication PMID: 22404213 
24 FLG up HSV-1 replication, HPV-related cancers PMID: 23657503, PMID: 24905740 
25 ACO1 up COVID-19 related up-regulation PMID: 33437935 
26 ADCY3 down ZIKA pathogenicity PMID: 30222212 
27 ANKLE2 down Zika virus targeted PMID: 31735666 
28 BTBD2 down restrict HIV-1 infection PMID: 21092135 
29 CCNH up HCV induced upregulation PMID: 27742031 
30 DDX55 up IAV life cycle PMID: 27653209 
31 DKC1 up HCC, influenza virus infection PMID: 22912812, PMID: 24955349 
32 DNAL1 up HIV-1 restriction PMID: 22018492 
33 FDFT1 up regulates HCV propagation PMID: 24690320 
34 PEX13 down HIV-1, HCMV, HSV-1 and ZIKA virus; autophagy PMID: 28594894, PMID: 32127461, PMID: 30269970, PMID: 31311201, 
PMID: 27827795 
35 RFX7 up HSV-1 PMID: 29114028 
36 SEC14L2 down promote HCV replication PMID: 26266980, PMID: 30472319 
37 SLC35D1 down cell survival upon VSV infection PMID: 31320712 
Cell-to-cell 
Adhesion 
38 CLDN5 down Tight junction protein ShinyGO v0.61: Gene Ontology Enrichment Analysis 
39 MAGI2 down Tight junction protein ShinyGO v0.61: Gene Ontology Enrichment Analysis 
40 FBLIM1 down Cell-cell adhesion, cell junction organization ShinyGO v0.61: Gene Ontology Enrichment Analysis 
41 VEZT up cell-cell adhesion; tumor suppressor ShinyGO v0.61: Gene Ontology Enrichment Analysis, PMID: 24069310 
42 PRICKLE3 up cell polarity protein, scaffold/adaptor protein ShinyGO v0.61: Gene Ontology Enrichment Analysis 
HCC or Cancer 
Associated 
43 EXOSC9 down its depletion attenuates tumorigenicity PMID: 32518284 
44 HOMER2 up HCC PMID: 29556326 
45 HSF1 down HCC progression, highly expressed in HBV infected patients PMID: 25199534, PMID: 30214576 
46 INO80C up tumor suppressor PMID: 28954733 
47 NFYC up HCC PMID: 29774579 
48 RFFL down highly upregulated in HCC-R tumor tissues PMID: 24377043 
49 MED30 down HBV integration in tumor cells PMID: 31200735 
50 SSTR5 down HBV-related HCC PMID: 31638225, PMID: 24137418 
51 TP53 up HCC PMID: 21760996 
52 FLG2 up HBV-related HCC PMID: 32017470 
53 BAD down HCC PMID: 16807152 
54 CAB39L down tumor suppressor PMID: 30054562 
55 SMARCA4 down HCC PMID: 29352111 
56 NT5E up cancer and immunosuppressive effects PMID: 25298403, PMID: 29720980 




a   Genes associated in both virus infection and cancer development are bolded. Genes analyzed in this study are 
shown in with a white box; those not analyzed are indicated with a grey box.  
 
 
 
 
